# David A Lomas

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8301121/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 95 papers | 9,387 citations | 71102 41 h-index | 39675 94 g-index |
| 99 all docs | 99 docs citations | 99 times ranked | 8269 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. Gut, 2022, 71, 415-423. | 12.1 | 28 |
| 2 | Alpha-1 Antitrypsin MZ Heterozygosity Is an Endotype of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 313-323. | 5.6 | 21 |
| 3 | The molecular species responsible for Î± 1 â€antitrypsin deficiency are suppressed by a small molecule chaperone. FEBS Journal, 2021, 288, 2222-2237. | 4.7 | 8 |
| 4 | Conversion of the death inhibitor ARC to a killer activates pancreatic Î² cell death in diabetes. Developmental Cell, 2021, 56, 747-760.e6. | 7.0 | 8 |
| 5 | InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. Respiratory Research, 2021, 22, 130. | 3.6 | 9 |
| 6 | The Importance of N186 in the Alpha-1-Antitrypsin Shutter Region Is Revealed by the Novel Bologna Deficiency Variant. International Journal of Molecular Sciences, 2021, 22, 5668. | 4.1 | 5 |
| 7 | Quantitative <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography to assess pulmonary inflammation in COPD. ERJ Open Research, 2021, 7, 00699-2020. | 2.6 | 2 |
| 8 | Scaling Concepts in Serpin Polymer Physics. Materials, 2021, 14, 2577. | 2.9 | 4 |
| 9 | The development of highly potent and selective small molecule correctors of Z Î±1-antitrypsin misfolding. Bioorganic and Medicinal Chemistry Letters, 2021, 41, 127973. | 2.2 | 9 |
| 10 | Development of a small molecule that corrects misfolding and increases secretion of Z Î± <sub>1</sub> â€antitrypsin. EMBO Molecular Medicine, 2021, 13, e13167. | 6.9 | 33 |
| 11 | The structural basis for Z Î± <sub>1</sub> -antitrypsin polymerization in the liver. Science Advances, 2020, 6, . | 10.3 | 26 |
| 12 | High-resolution ex vivo NMR spectroscopy of human Z Î±1-antitrypsin. Nature Communications, 2020, 11, 6371. | 12.8 | 15 |
| 13 | Heme metabolism genes Downregulated in COPD Cachexia. Respiratory Research, 2020, 21, 100. | 3.6 | 4 |
| 14 | Alpha<sub>1</sub>-Antitrypsin Deficiency. New England Journal of Medicine, 2020, 382, 1443-1455. | 27.0 | 269 |
| 15 | Intrahepatic heteropolymerization of M and Z alpha-1-antitrypsin. JCI Insight, 2020, 5, . | 5.0 | 16 |
| 16 | C. elegans expressing D76N Î²2-microglobulin: a model for in vivo screening of drug candidates targeting amyloidosis. Scientific Reports, 2019, 9, 19960. | 3.3 | 14 |
| 17 | Calcium signalling in mammalian cell lines expressing wild type and mutant human Î±1-Antitrypsin. Scientific Reports, 2019, 9, 17293. | 3.3 | 3 |
| 18 | Characterisation of a type II functionally-deficient variant of alpha-1-antitrypsin discovered in the general population. PLoS ONE, 2019, 14, e0206955. | 2.5 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. New England Journal of Medicine, 2018, 378, 1671-1680. | 27.0 | 823 |
| 20 | Fibrinogen does not relate to cardiovascular or muscle manifestations in COPD: cross-sectional data from the ERICA study. Thorax, 2018, 73, 1182-1185. | 5.6 | 9 |
| 21 | Heteropolymerization of Î±-1-antitrypsin mutants in cell models mimicking heterozygosity. Human Molecular Genetics, 2018, 27, 1785-1793. | 2.9 | 24 |
| 22 | An automated high-throughput system for phenotypic screening of chemical libraries on C. elegans and parasitic nematodes. International Journal for Parasitology: Drugs and Drug Resistance, 2018, 8, 8-21. | 3.4 | 71 |
| 23 | In Vitro Approaches for the Assessment of Serpin Polymerization. Methods in Molecular Biology, 2018, 1826, 87-107. | 0.9 | 0 |
| 24 | Î±1-Antitrypsin Polymerizes in Alveolar Macrophages of Smokers With and Without Î±1-Antitrypsin Deficiency. Chest, 2018, 154, 607-616. | 0.8 | 22 |
| 25 | The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial. PLoS ONE, 2018, 13, e0194197. | 2.5 | 23 |
| 26 | New Therapeutic Targets for Alpha-1 Antitrypsin Deficiency. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2018, 5, 233-243. | 0.7 | 18 |
| 27 | Taking out the JuNK to treat Î±1-antitrypsin deficiency. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 201-202. | 17.8 | 1 |
| 28 | The pathological Trento variant of alphaâ€1â€antitrypsin (E75V) shows nonclassical behaviour during polymerization. FEBS Journal, 2017, 284, 2110-2126. | 4.7 | 23 |
| 29 | Body mass index change in gastrointestinal cancer and chronic obstructive pulmonary disease is associated with Dedicator of Cytokinesis 1. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 428-436. | 7.3 | 13 |
| 30 | Sex-Based Genetic Association Study Identifies CELSR1 as a Possible Chronic Obstructive Pulmonary Disease Risk Locus among Women. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 332-341. | 2.9 | 28 |
| 31 | An antibody that prevents serpin polymerisation acts by inducing a novel allosteric behaviour. Biochemical Journal, 2016, 473, 3269-3290. | 3.7 | 15 |
| 32 | Update on alpha-1 antitrypsin deficiency: New therapies. Journal of Hepatology, 2016, 65, 413-424. | 3.7 | 66 |
| 33 | The endoplasmic reticulum remains functionally connected by vesicular transport after its fragmentation in cells expressing Zâ€Î±<sub>1</sub>â€antitrypsin. FASEB Journal, 2016, 30, 4083-4097. | 0.5 | 22 |
| 34 | An ECLIPSE View of Alpha-1 Antitrypsin Deficiency. Annals of the American Thoracic Society, 2016, 13, S326-S331. | 3.2 | 11 |
| 35 | Î±1-Antitrypsin deficiency. Nature Reviews Disease Primers, 2016, 2, 16051. | 30.5 | 215 |
| 36 | Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. European Respiratory Journal, 2016, 47, 1365-1373. | 6.7 | 64 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Polymers of Z Î±<sub>1</sub>-antitrypsin are secreted in cell models of disease. European Respiratory Journal, 2016, 47, 1005-1009. | 6.7 | 41 |
| 38 | Deficiency Mutations of Alpha-1 Antitrypsin. Effects on Folding, Function, and Polymerization. American Journal of Respiratory Cell and Molecular Biology, 2016, 54, 71-80. | 2.9 | 31 |
| 39 | Does Protease-Antiprotease Imbalance Explain Chronic Obstructive Pulmonary Disease?. Annals of the American Thoracic Society, 2016, 13 Suppl 2, S130-7. | 3.2 | 25 |
| 40 | An integrative approach combining ion mobility mass spectrometry, Xâ€ray crystallography, and nuclear magnetic resonance spectroscopy to study the conformational dynamics of Î±<sub>1</sub>â€antitrypsin upon ligand binding. Protein Science, 2015, 24, 1301-1312. | 7.6 | 37 |
| 41 | Characterising the association of latency with Î±1-antitrypsin polymerisation using a novel monoclonal antibody. International Journal of Biochemistry and Cell Biology, 2015, 58, 81-91. | 2.8 | 26 |
| 42 | Circulating Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Biomarker of Emphysema and the RAGE Axis in the Lung. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 785-792. | 5.6 | 82 |
| 43 | An antibody raised against a pathogenic serpin variant induces mutant-like behaviour in the wild-type protein. Biochemical Journal, 2015, 468, 99-108. | 3.7 | 22 |
| 44 | A singleâ€chain variable fragment intrabody prevents intracellular polymerization of Z Î± <sub>1</sub> â€antitrypsin while allowing its antiproteinase activity. FASEB Journal, 2015, 29, 2667-2678. | 0.5 | 44 |
| 45 | The TRiC/CCT Chaperone Is Implicated in Alzheimer's Disease Based on Patient GWAS and an RNAi Screen in AÎ²-Expressing Caenorhabditis elegans. PLoS ONE, 2014, 9, e102985. | 2.5 | 34 |
| 46 | Altered native stability is the dominant basis for susceptibility of Î±1-antitrypsin mutants to polymerization. Biochemical Journal, 2014, 460, 103-119. | 3.7 | 25 |
| 47 | Circulating polymers in Â1-antitrypsin deficiency. European Respiratory Journal, 2014, 43, 1501-1504. | 6.7 | 69 |
| 48 | S51 Circulating Desmosine Relates To Cardiovascular Comorbidity, Coronary Artery Calcification Score (cacs), Systemic Inflammation And Mortality In Patients With Copd. Thorax, 2014, 69, A28-A29. | 5.6 | 1 |
| 49 | Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax, 2014, 69, 718-723. | 5.6 | 151 |
| 50 | The molecular and cellular pathology of Î±1-antitrypsin deficiency. Trends in Molecular Medicine, 2014, 20, 116-127. | 6.7 | 98 |
| 51 | Lessons from ECLIPSE: a review of COPD biomarkers. Thorax, 2014, 69, 666-672. | 5.6 | 125 |
| 52 | Susceptibility to Chronic Mucus Hypersecretion, a Genome Wide Association Study. PLoS ONE, 2014, 9, e91621. | 2.5 | 25 |
| 53 | p53 and Translation Attenuation Regulate Distinct Cell Cycle Checkpoints during Endoplasmic Reticulum (ER) Stress. Journal of Biological Chemistry, 2013, 288, 7606-7617. | 3.4 | 35 |
| 54 | Twenty Years of Polymers: A Personal Perspective on Alpha-1 Antitrypsin Deficiency. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 17-25. | 1.6 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Reactive centre loop mutants of Î±-1-antitrypsin reveal position-specific effects on intermediate formation along the polymerization pathway. Bioscience Reports, 2013, 33, . | 2.4 | 24 |
| 56 | Endoplasmic reticulum polymers impair luminal protein mobility and sensitize to cellular stress in alpha<sub>1</sub>â€antitrypsin deficiency. Hepatology, 2013, 57, 2049-2060. | 7.3 | 108 |
| 57 | An Oral Inhibitor of p38 MAP Kinase Reduces Plasma Fibrinogen in Patients With Chronic Obstructive Pulmonary Disease. Journal of Clinical Pharmacology, 2012, 52, 416-424. | 2.0 | 99 |
| 58 | Structural Dynamics Associated with Intermediate Formation in an Archetypal Conformational Disease. Structure, 2012, 20, 504-512. | 3.3 | 33 |
| 59 | Targeted gene correction of Î±1-antitrypsin deficiency in induced pluripotent stem cells. Nature, 2011, 478, 391-394. | 27.8 | 635 |
| 60 | Characterisation of serpin polymers in vitro and in vivo. Methods, 2011, 53, 255-266. | 3.8 | 31 |
| 61 | Therapeutic target-site variability in Î±<sub>1</sub>-antitrypsin characterized at high resolution. Acta Crystallographica Section F: Structural Biology Communications, 2011, 67, 1492-1497. | 0.7 | 39 |
| 62 | The Serpinopathies. Methods in Enzymology, 2011, 501, 421-466. | 1.0 | 35 |
| 63 | A novel monoclonal antibody to characterize pathogenic polymers in liver disease associated with Î±<sub>1</sub>-antitrypsin deficiency. Hepatology, 2010, 52, 1078-1088. | 7.3 | 138 |
| 64 | Defining the mechanism of polymerization in the serpinopathies. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17146-17151. | 7.1 | 135 |
| 65 | 25th Anniversary Transatlantic Airway Conference: Protein Misfolding and Obstructive Lung Disease. Proceedings of the American Thoracic Society, 2010, 7, 343-345. | 3.5 | 1 |
| 66 | Conformational Pathology of the Serpins: Themes, Variations, and Therapeutic Strategies. Annual Review of Biochemistry, 2009, 78, 147-176. | 11.1 | 239 |
| 67 | Crystallographic and Cellular Characterisation of Two Mechanisms Stabilising the Native Fold of Î±1-Antitrypsin: Implications for Disease and Drug Design. Journal of Molecular Biology, 2009, 387, 857-868. | 4.2 | 34 |
| 68 | Sex Differences in Emphysema and Airway Disease in Smokers. Chest, 2009, 136, 1480-1488. | 0.8 | 88 |
| 69 | The intracellular accumulation of polymeric neuroserpin explains the severity of the dementia FENIB. Human Molecular Genetics, 2008, 17, 1527-1539. | 2.9 | 95 |
| 70 | Genetic predisposition to chronic obstructive pulmonary disease: advances in Î±<sub>1</sub>-antitrypsin deficiency and the serpinopathies. Clinical Medicine, 2007, 7, 446-447. | 1.9 | 7 |
| 71 | Parker B. Francis Lectureship. Antitrypsin Deficiency, the Serpinopathies, and Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2006, 3, 499-501. | 3.5 | 11 |
| 72 | The Selective Advantage of Î±<sub>1</sub>-Antitrypsin Deficiency. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1072-1077. | 5.6 | 79 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Molecular mousetraps, Î±<sub>1</sub>-antitrypsin deficiency and the serpinopathies. Clinical Medicine, 2005, 5, 249-257. | 1.9 | 45 |
| 74 | Latent S49P Neuroserpin Forms Polymers in the Dementia Familial Encephalopathy with Neuroserpin Inclusion Bodies. Journal of Biological Chemistry, 2005, 280, 13735-13741. | 3.4 | 51 |
| 75 | Polymers of Z Î±1-Antitrypsin Co-Localize with Neutrophils in Emphysematous Alveoli and Are Chemotactic in Vivo. American Journal of Pathology, 2005, 166, 377-386. | 3.8 | 180 |
| 76 | Mutants of Neuroserpin That Cause Dementia Accumulate as Polymers within the Endoplasmic Reticulum. Journal of Biological Chemistry, 2004, 279, 28283-28291. | 3.4 | 102 |
| 77 | Targeting a Surface Cavity of Î±1-Antitrypsin to Prevent Conformational Disease. Clinical Science, 2003, 104, 57P-57P. | 0.0 | 0 |
| 78 | Serpinopathies and the conformational dementias. Nature Reviews Genetics, 2002, 3, 759-768. | 16.3 | 211 |
| 79 | Î±1-Antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. Journal of Clinical Investigation, 2002, 110, 1585-1590. | 8.2 | 199 |
| 80 | Î±1-Antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. Journal of Clinical Investigation, 2002, 110, 1585-1590. | 8.2 | 134 |
| 81 | Polymerization of Plasminogen Activator Inhibitor-1. Journal of Biological Chemistry, 2001, 276, 9115-9122. | 3.4 | 52 |
| 82 | A novel polymorphism (471C?T) in alpha-1-antitrypsin in a patient with asthma. Human Mutation, 2001, 17, 155-156. | 2.5 | 5 |
| 83 | Characterization of a new variant of ?1-antitrypsin EJohannesburg (H15N) in association with asthma. Human Mutation, 2001, 17, 156-156. | 2.5 | 7 |
| 84 | The Serpins Are an Expanding Superfamily of Structurally Similar but Functionally Diverse Proteins. Journal of Biological Chemistry, 2001, 276, 33293-33296. | 3.4 | 1,069 |
| 85 | Topography of a 2.0 Ã... structure of Î±<sub>1</sub>â€antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Science, 2000, 9, 1274-1281. | 7.6 | 177 |
| 86 | Familial dementia caused by polymerization of mutant neuroserpin. Nature, 1999, 401, 376-379. | 27.8 | 342 |
| 87 | A Kinetic Mechanism for the Polymerization of Î±1-Antitrypsin. Journal of Biological Chemistry, 1999, 274, 9548-9555. | 3.4 | 205 |
| 88 | A 2.6 Ã¥ structure of a serpin polymer and implications for conformational disease 1 1Edited by R. Huber. Journal of Molecular Biology, 1999, 293, 449-455. | 4.2 | 116 |
| 89 | Heteropolymerization of S, I, and Z Î±1-antitrypsin and liver cirrhosis. Journal of Clinical Investigation, 1999, 103, 999-1006. | 8.2 | 172 |
| 90 | Lung Polymers in Z Î±<sub>1</sub>-Antitrypsin Deficiency-related Emphysema. American Journal of Respiratory Cell and Molecular Biology, 1998, 18, 670-674. | 2.9 | 132 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Î±1-Antitrypsin Deficiency. Chest, 1996, 110, 243S-247S. | 0.8 | 52 |
| 92 | Structural explanation for the deficiency of S Î±1-antitrypsin. Nature Structural Biology, 1996, 3, 910-911. | 9.7 | 87 |
| 93 | Î±1-Antitrypsin Mmalton (Phe52-deleted) Forms Loop-Sheet Polymers in Vivo.. Journal of Biological Chemistry, 1995, 270, 16864-16870. | 3.4 | 133 |
| 94 | Effect of the Z mutation on the physical and inhibitory properties of .alpha.1-antitrypsin. Biochemistry, 1993, 32, 500-508. | 2.5 | 229 |
| 95 | The mechanism of Z Î±1-antitrypsin accumulation in the liver. Nature, 1992, 357, 605-607. | 27.8 | 1,020 |